Amniotics led EIC-Pathfinder 3.8 M€ oncology project has started
Funded By EU
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Sektor | Hälsovård |
| Industri | Bioteknik |
Amniotics AB (publ) (Nasdaq Stockholm: AMNI) today announces that the European Innovation Council (EIC) funded HyperTargIPS-NK EIC Pathfinder project has been formally initiated.
A consortium led by Amniotics has been funded by EU with €3.8 Million over three years for the development of iPS derived enhanced Natural Killer (NK) cells. The other consortium participants are Lund University, Medizinische Hochschule Hannover, and University of Copenhagen.
The goal of the HyperTargIPS-NK project is to combine novel technologies from the three research laboratories with Amniotics expertise to develop a revolutionary therapeutic modality for patients with cancer. The proposed treatment is based on laboratory generated natural killer (NK) cells, genetically modified to a hyperactive state to ensure elimination of the tumor cells.
-It is a great honor for Amniotics to be a part of this consortium which aims to bring transformative therapies to cancer patients. Amniotics has a patent portfolio within the area of blood cell production and NK cells, thus our participation in this EU project is of particular value to the company’s future cell therapy development, says Jan Talts, COO of Amniotics and the project coordinator.